Skip to Content
Søg Menu

ASCO20: What are the key clinical messages from the SPARTAN study?

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on survival.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
ASCO20Prostatacancer

ASCO20: Key takeways from ASCO20 Virtual in prostate cancer

/ Eric J. Small
ASCO20Prostatacancer Play the Video 2:23

ASCO20: Patients with non metastatic castration resistant prostate cancer

/ Eric J. Small
ASCO20Prostatacancer Play the Video 2:03

ASCO20: Can you describe what characterizes the group of patients with non-metastatic castration-resistant prostate cancer?

/ Eric J. Small
ASCO20Prostatacancer Play the Video 5:49

ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

/ Eric J. Small
ASCO20Prostatacancer Play the Video 0:58

ASCO20: Why has non-metastatic castration-resistant prostate cancer become interesting?

/ Eric Small
ASCO20Prostatacancer Play the Video 2:34

ASCO20: What was the background and study design of the SPARTAN study?

/ Eric Small
ASCO20Prostatacancer Play the Video 3:14
Back to top